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Perinatal drug abuse is becoming a profound issue facing the health and wellbeing of 
neonates. The community serviced by the project site, which lies within the boundaries of 
an Indian Reservation, suffers from perinatal drug abuse at a higher rate than state and 
federal averages. The purpose of this project was to provide the project site with a policy 
to consistently screen for perinatal drug abuse. Lave’s theory of situational learning and 
the Sanford Way model for quality improvement framed this project. To guide policy 
development, data were compiled through a systematic review of current literature, 
national and state guidelines, state law, local tribal government, and community 
stakeholders.  Data included: (a) studies completed in the past 10 years specifically 
targeting drug abuse in child-bearing aged women, with intentional exclusion of tobacco 
and alcohol studies; (b) prevalence of illicit drug abuse in child bearing aged women at a 
local, state, and national levels; and (c) local, state, and national guidelines, as well as 
state law, for perinatal drug abuse intervention and screening. In addition, interviews and 
meetings with local stakeholders were completed and their feedback was incorporated 
into the development of the perinatal drug abuse screening and intervention policy. To 
evaluate policy effectiveness, it is proposed that perinatal drug screens ordered at the 
project site be monitored for six months prior to and after implementation of the new 
policy. The desired outcome will be that providers consistently intervene with perinatal 
drug abuse in a non-biased fashion. This quality improvement project will create a 
positive social change by allowing non-biased intervention with perinatal drug abuse 
using evidence-based practice and by promoting nursing-driven policy development.  
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Section 1: Nature of the Project 
Section 1 
Introduction 
It was not until the early 1970’s that teratogens such as alcohol were identified as 
causing adverse infant outcomes, and it was not until 1990 that the Alcohol Beverage 
Labeling Act of 1988 went into effect. This was the first intervention by the Surgeon 
General focusing on substance abuse of pregnant women (Grant, 2009). According to the 
literature, little has changed since the discovery of this public health concern. There are 
more deaths, illnesses, and disabilities from substance abuse than from any other 
preventable health condition (Healthy People, 2010). Perinatal drug abuse has become a 
recognized health disparity of epidemiologic proportions (ASTHO, 2014). Infants 
exposed to drugs during pregnancy can be diagnosed with neonatal abstinence syndrome 
(NAS), requiring extensive medical treatment at birth and beyond. In the US, NAS rates 
increased from 1.2 per 1,000 infants to 3.9 per 1,000 infants in 2009 alone (ASTHO, 
2014). There has been a 33% increase in non-medical, opioid pain reliever use among 
pregnant women in the past decade (ASTHO, 2014). Early treatment and intervention is 
the key to successful outcomes for infants affected by substance abuse. Many studies 
show that substance using women, particularly cocaine or opiate users, are significantly 
less likely to obtain prenatal care (Schempf, 2009) and that substance abuse during the 




Perinatal drug abuse is a growing problem for all communities in the United 
States. The healthcare facility for this project is a critical access emergency department, 
hospital, and rural health clinic located in northern Minnesota. The county in which the 
facility lies is within the borders of an Indian Reservation. The project facility does not 
currently have a policy on perinatal drug testing or perinatal drug use intervention. The 
purpose of this project is to develop a policy to guide health care providers to test for and 
intervene in perinatal drug abuse.  
Facilities such as the project facility may be the only contact mothers have with 
health care during their pre-conception, perinatal, and postnatal care states. It is very 
important for health care providers to recognize the symptoms of drug abuse in women of 
child bearing age and to have a policy for testing and intervention 
Problem Statement 
The state of Minnesota has been consistently ranked one of the lowest infant 
mortality states in the US (MDH, 2013). However, Minnesota’s American Indian 
children have a twofold greater incidence, compared to any other ethnic group of infant 
mortality in their first year of life (MDH, project site, 2013). The county where the 
project site is located has the highest rates of teen pregnancy, sexually transmitted 
diseases, and drug and alcohol abuse among child bearing-aged women and the lowest 
number of primary care providers per capita in the state (MDH, 2013). According to the 
State Substance Use Report (2014), the students and adults in the county where the 
project site resides are “considerably more likely to use tobacco, alcohol, illicit drugs and 
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marijuana” (more than double the state average in all areas) than any other resident in the 
state (SUMN, 2014).  
Purpose Statement  
According to Association of State and Territorial Health Officials (ASTHO) 
(2014), “taking a public health approach to routine screening for unhealthy substance use 
in women at every healthcare visit can help increase the opportunities for primary 
prevention” (p. 2). The purpose of this project is to develop a healthcare facility policy to 
guide health care providers to test for and intervene in perinatal drug abuse. 
Project Goals and Objectives 
The goal for this project is to develop a policy for the project site that will enable 
providers (Nurse Practitioners and Physicians) to objectively screen child-bearing aged 
women for drug abuse, by providing hospital and emergency department caregivers the 
policy support needed to test for, and intervene with, positive drug screens.  
Currently, the project site does not have a policy that will guide providers in 
perinatal drug screening. This makes providers vulnerable to the assumption of bias when 
testing or intervening with perinatal drug abuse. Globally, this project will remove those 
assumptions of bias and give providers the support needed to properly intervene in 
perinatal drug abuse. Specific objectives for this project will be to develop a perinatal 
drug abuse policy based on National Guidelines established by the American Academy of 
Pediatrics, American Academy of Obstetrics, Registered Nurses Association of Ontario, 
evidence (Cochrane reviews), state law, and local tribal government recommendations.  
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After graduation, future plans will be for project site leadership to implement the 
policy system-wide for all health care providers to follow, as well as develop a formal 
education program for all healthcare providers that will expand their understanding of 
perinatal drug abuse. This quality improvement project will have future goals to lead this 
facility towards a program that will (a) identify health care providers’ current philosophy 
on drug screening, (b) educate providers on the need for a policy to manage perinatal 
drug abuse, (c) develop a policy for all emergency room and hospital providers to test for 
perinatal drug abuse, and (d) establish a protocol for intervention when perinatal drug 
abuse is diagnosed.  
Theoretical Framework 
Lave and Wenger developed a learning theory based on the assumption that 
individuals learn according to the situation they are in and that there is a direct correlation 
between learning and the situation the individual is in (Wenger, 1991). Laves Theory of 
Situation Learning will be used as a theoretical framework when developing the project.  
Laves theory implies that learning requires that the context of information be presented as 
authentic and that it take place in settings and situations in which it would normally occur 
(Knowledgebase, 2011). Laves theory is a practice theory and requires interaction 
between all parties. (Knowledgebase, 2011).  
Significance to Practice 
Nurses are not typically strong in policy development and are historically known 
to “shy away from leadership opportunities” (Mason, 2013, p. xxvii). Doctorate-prepared 
nurses are called upon to lead their field in policy development and social change. 
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Development of system policy, by nurses, will positively impact the future of nursing 
mentorship within the nursing profession. Nursing is working diligently to develop a 
culture of nursing mentorship within this profession that goes above and beyond the 
individual and organizational level (Montavlo, 2015).  
Evidence-Based Significance 
The need to screen, test, and intervene with perinatal drug abuse is a lake filled 
with murky water for practicing providers. Prescription drug abuse in the US alone has 
reached epidemic proportions. McHugh (2015) stated “The rapid escalation of this 
problem initially far outpaced clinical research on its nature and on interventions to 
prevent and treat prescription drug use disorders” (p. 2). Providers are unclear of their 
role in perinatal drug abuse and are in need of evidence-based policies that will guide 
their assessment and intervention of this epidemic problem.  
Implications for Social Change 
 The Child Abuse and Prevention and Treatment Act (CAPTA) was amended in 
2003 to include the “Keeping Children and Families Safe Act” which allows funding for 
states contingent on their establishment of procedures that keep safe infants born to illicit 
drug abuse (Farst, 2011). This act provides protection to providers to screen for drug 
abuse in pregnancy, but leaves the decision of who and when to test at the discretion of 
the provider. Farst (2011) stated objective protocols are needed to avoid bias towards 
newborns of minority or poverty backgrounds. To avoid the suspicion of provider bias, 
every healthcare facility should develop a policy to address perinatal drug abuse testing 
(Farst, 2011).  
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Definition of Terms 
The principal terms used throughout this QI project are defined next. 
Perinatal: According to the World Health Organization (WHO), perinatal period 
begins at 22 weeks gestation and ends at 7 days post-partum (WHO, 2013).  
Illicit drug abuse: For this purpose of this project, illicit drug abuse is limited to 
marijuana, opiate (prescription as well as non-prescription), methamphetamine, and other 
illegal chemicals for mood alteration.  
Critical access hospitals (CAH): Are rural hospitals that meet defined criteria 
outlined by the federal government and are reimbursed by cost-based measures (Center, 
2011).  
Screening: For the purpose of this project refers to the process of determining 
drug abuse in women in the perinatal period. Screening involves assessment of findings, 
lab testing, and history and physical exam.  
Neonatal Abstinence Syndrome (NAS): Is a syndrome of symptoms noted in 
infants during the perinatal period that is caused from a sudden cessation of exposure to 
illicit drugs. NAS is diagnosed by using the Finnegan Scoring System (Kocherlakota, 
2014).  
Limitations and Assumptions 
Limitations to development of a perinatal drug abuse policy at the project site are 
related to provider acceptance of policy and professional collaboration. Team approach is 
a strategy that will help facilitate physicians, nurses, and all other stakeholders engaged 
in perinatal drug abuse prevention, to work collaboratively to improve patient outcomes 
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(White, 2012). Assumptions for this quality improvement project are that the policy is 
designed specifically for the need of one facility, and that the goals, mission and vision of 
this project align specifically with this one facility. Limitations also include the fact that 
the DNP student researcher of this project is employed at the facility this program is 
being designed for. This will potentially create personal bias due to previous experience 
working with perinatal drug abuse in this facility.  Although this is a limitation, it can 
also be a benefit in that the DNP student is familiar with providers, facility processes, and 
the population served. 
Summary 
The project site is currently without a policy that can be used by emergency room 
and hospital providers when intervening with perinatal drug abuse. There is a need for a 
site-specific policy that will guide providers to intervene with perinatal drug abuse. 
Without a policy for intervention in place, providers are subject to accusations of bias. A 
perinatal drug abuse policy will provide an avenue for early recognition and intervention 










Section 2: Review of Literature and Theoretical and Conceptual Framework 
Literature Review 
Specific Literature 
Perinatal drug abuse and infants born with NAS have increased at an alarming 
rate in the US (Patrick, 2012). The project site does not currently have a policy that 
guides health care providers to screen, test, or intervene with perinatal drug use. Without 
a facility policy in place, it is left up to the discretion of the provider to determine the 
need for testing, relying on personal judgment (Birchfield, 1994). The project site is a 
critical access hospital and ED in an underserved, high risk county that was ranked the 
“least healthy county” in its home state in 2014 (Robert Wood Johnson, 2014). Testing 
and screening for perinatal drug abuse is critical to intervention (ASTHO, 2014). The 
purpose of this project is to develop a policy that will guide health care providers at the 
project site to screen and test for perinatal drug abuse and intervene when needed.  
Literature Search and Strategy 
Ten databases were used for the purpose of searching the literature. Google 
Scholar, Mayo Clinic, Sanford Health, Walden University Library database search of 
CINAHL, PubMed, MEDLINE, Nursing and Allied Health Score, and the Cochran 
Database of Systemic Reviews were searched. Key search terms used were 
 testing for drug abuse in pregnancy 
 health policy drug abuse 
 pregnancy drug abuse 
 pregnancy testing policy 
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 perinatal testing policy 
 neonatal abstinence syndrome 
 illicit drug abuse pregnancy 
 pregnancy outcomes 
 drug abuse pregnancy risk factors 
 Minnesota statues perinatal drug exposure 
 perinatal drug abuse 
The scope of the literature review for this paper was broad. Early literature on 
NAS and policy needs were found in the late 70s- early 90s. The majority of the literature 
used was collected from 2000- 2014.  
It is noted that a Tribal Chairwoman announced at the 14
th
 annual Communities 
Collaborative Brain Development Conference (held August 12-14, 2014) that 80% of all 
Native American babies born at two local birthing centers were positive for drugs. This is 
important to the findings for this paper as the project site lies entirely within the borders 
of and Indian Reservation, and is the only hospital and ED on this reservation. During the 
search for information it was noted that statistics and specific data regarding tribal 
members are protected, often not shared with non-tribal affiliates, or not collected at all. 
For the needs of this project, the evidence, literature and databases searched, were done 
so at a national, state, and county level and applied to this community. National, state and 
county data were reviewed for the purpose of this proposal, has been aggregated and 




Neonatal abstinence syndrome is a diagnosis given to infants born with specific 
symptoms of drug withdrawal at birth (Finnegan, 1974). The most commonly utilized 
tool for diagnosis of NAS is the Finnegan scoring system (Kushel, 2007). The Finnegan 
scoring system is a system that allows a health care provider to identify and score specific 
withdrawal symptoms. A Finnegan score above 7 typically indicates the need for 
treatment of NAS (Kushel, 2007). In the past decade there has been a significant rise in 
the number of US births diagnosed with NAS. Diagnosed cases have rose from 1.2 per 
1,000 US births to 3.39 per 1,000 births.  (ASTHO, 2014). More than 13,000 infants were 
born with drug withdrawal symptoms in 2009, which means approximately one infant is 
born with NAS every hour in the US (ASTHO, 2014).  This is likely not a true 
representation of the number of infants born with NAS, as maternal drug abuse is under-
reported, there is commonly no prenatal care, infants are born outside of a health care 
setting, and Finnegan scoring is subjective to user assessment (Houdak, 2012). In 2013 
The Department of Health & Human Services, Substance Abuse and Mental Health 
Services (SAMHSA), released the results from their 2012 National Survey on drug abuse 
and reported that among pregnant women, aged 15 to 44 years, 4.0% used illicit drugs in 
the past month, 11.8% reported current alcohol use, 2.9% reported binge drinking, and 
16.5% of pregnant women used tobacco in the last month.2 In the United States, nearly 
90% of drug-abusing women are of reproductive age. Substances most commonly abused 
during pregnancy include cocaine, amphetamines, opioids, marijuana, ethanol, tobacco, 
caffeine, and toluene-based solvents. 
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Great controversy surrounds perinatal drug screening. The need for policy to 
guide testing has increased as the number of infants born with exposure has increased. In 
an early study on the need for policies to test for drug abuse in pregnant women, 
Birchfield (1994) stated, “the process by which pregnant women and infants are selected 
for illicit drug testing has caused concern because it may lead to bias and 
overrepresentation of certain populations in the drug-using groups.” (p. 211). The 
Association of State and Territorial Health Officials (ASTHO) suggested that “taking a 
public health approach to routine screening for unhealthy substance use in women at 
every healthcare visit can help increase the opportunities for primary prevention” and 
recognizes the following lifetime frames as key time frames for interventions 
“preconception, during pregnancy, at birth, postpartum or neonatal/infancy period, and 
childhood and beyond” (ASTHO, 2014, p.3). 
Lindsay (2013) recommended “parturients identified as drug users” receive a 
comprehensive management approach involving both “high risk obstetrics, and 
comprehensive counseling” (p. 140). Recognition of this profound social problem has 
healthcare leaders pushing for universal screening of all child bearing aged women, and 
certainly for all pregnant women. ASTHO (2014) stated:  
States can support the American Congress of Obstetricians and Gynecologists’ 
(ACOG) recommendation for universal substance use screening in early 
pregnancy in a variety of ways. State agencies, quality improvement efforts, and 
perinatal collaborative can advance prenatal screenings as the expected standard 
of care for obstetric providers. State health agencies can ensure that Medicaid 
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reimburses for substance abuse screening, support provider education and 
training, and streamline entry points for substance abuse treatment. Need page 
number 
The literature regarding perinatal substance abuse has proved consistent results. 
There is a national, as well as, global need for interventions surrounding perinatal 
substance abuse. In addition, there is a need for further screening and policies for drug 
screening and testing, which are specific to women, and pregnant women. For the 
purpose of this study, emphasis will be placed on those studies that only address 
substance abuse in pregnancy and reproductive aged women.  
Perinatal Drug Abuse Studies 
The following review will examine: (a) five quantitative research studies 
conducted by Azadi and Dildy (2008), Pinto et al. (2010), Schempf and Strobino, (2009), 
Smith et al. (2009), and Vucinovic et al. (2008); (b) two qualitative studies by Nueshotz 
and Fitzpatrick (2008) and Walkup et al. (2009); and, (c) two meta-analyses conducted 
by Greenfield et al. (2010) and Howell et al. (1998).   
Purposes 
One quantitative and one qualitative article focused on identifying the prevalence 
of substance abuse, as well as, factors that interfere with screening and intervention of 
substance abuse problems (Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008).  Two 
quantitative studies focused on the contribution of substance abuse to negative outcomes 
in pregnancy (Pinto et al., 2010; Vucinovic et al.. 2008). Two quantitative studies focused 
on the correlation of maternal substance abuse and little to no prenatal or mental health 
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care (Schempf et al., 2009; Smith et al., 2009). The purpose of one qualitative study was 
to evaluate the efficacy of a home-visit intervention program among young, reservation 
based American Indian mothers and their increased parenting knowledge, including a 
reduction in perinatal substance abuse (Walkup, 2009).  
Designs      
Due to the nature of perinatal substance abuse and the fear of stigmatization and 
discrimination, many pregnant women keep the use of illicit drugs from their providers. 
Because of this, it is not surprising that the large majority of controlled studies are 
retrospective cohort studies (Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008; Pinto 
et a.., 2010; Schempf & Strobiono, 2009; Smith et al., 2009; and Vucinovic, 2008). All 
six of the retrospective studies were longitudinal with durations ranging from four 
months to ten years. One research study used a longitudinal, double blind trial of a home 
based intervention for young reservation based American Indian mothers (Walkup,  
2009).  
Samples 
Sampling refers to the way study participants are selected, and a sample refers to 
the segment of a population that is selected to participate in the study (Rubin, 2008). 
Many of the quantitative studies had large sampling sizes. For example, Vucinovic et al. 
(2008) looked at statistical data from 43,181 deliveries at Split University Hospital in 
Croatia, this was the only study noted using data from outside the US. This sampling 
method resulted in a study sample of 85 mothers that continued in the study. The samples 
in the quantitative studies varied greatly from 85 in the study by Vucinovic (2008) to 812 
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in the study by Schempf (2009). Of the randomized controlled trials, one had a sample 
size of 167 (Walkup et al., 2009) and one study did not clearly identify the sampling 
process or the sample size (Neushotz & Fitzpatrick, 2008).  
Methods and Measures 
Methods and measures varied between the studies. Three of the quantitative 
articles specifically noted only using data analysis (Pinto et al., 2010; Schempf & 
Strobino, 2009; Vucinovic et al., 2008).  The data gathered and analyzed by Pinto et al., 
(2010) came from patients’ records and specifically focused on demographic details, 
smoking, and past and present history of drug use, current antenatal problems, and self-
reported or clinically discovered substance use. Schempf and Stobino (2009) focused on 
data pertaining to low income, one or no prenatal visits, and positive drug screens. 
Vucinovic et al., (2008) analyzed data on all pregnancies complicated by illicit drug use 
over a 10 year period at Split University Hospital. 
Azadi and Dildy (2008) screened pregnant women who delivered at University 
Hospital in New Orleans in the first four months of 2005. On admission for labor, women 
were screened by urine toxicology testing for substance use. Demographic, labor, and 
outcome data were obtained from the records of those patients who tested positive. Those 
patients were also interviewed at the hospital during their labor admission. Those with 
positive urine toxicology screens and negative delivery outcomes were included in the 
sample. In the study by Smith et al. (2009), pregnant and postpartum women who tested 
positive underwent a diagnostic evaluation, were provided at least one mental health 
referral, and were encouraged to seek treatment for substance abuse, as well as, 
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depressive disorders. Follow up evaluations were done on these women at one month, 
three months, and six months. Logistic regression was used to estimate the relationship 
between clinical and psychosocial factors and self-reported mental health service use.  
The qualitative studies had two different methods and measures. Neushotz and 
Fitzpatrick (2008) conducted interviews with the clinic staff from a major metropolitan 
academic hospital in New York City. The staff included Physicians, Resident Physicians, 
one Social Worker, and seven Registered Nurses. The initial interview was conducted 
with the Director of Nurses and the Medical Chief.  Notes, reflections, and recordings of 
the meetings between the clinicians were analyzed extracting information on adherence 
to current practice guidelines regarding substance abuse screening. Walkup et al. (2009) 
conducted a study of expectant American Indian mothers aged 12-22 years randomized 
into one of two home visit intervention groups. The intervention began during pregnancy 
and continued to six months postpartum. They focused on prenatal and newborn care 
with specific emphasis on substance abuse, among other things.  Mothers and children 
were evaluated at baseline, two months, six months, and twelve months post-partum.  
Approaches to Analysis  
Data were collected and recorded in a number of different data bases. Stata was 
used by Pinto et al. (2010), Microsoft Office Access was used by Azadi & Dildy (2008), 
and Vucinovic et al., (2008) reported using SPSS 10. Five studies reported using the chi-
square test to determine bivariate associations between factors, namely the variables and 
controls. Four of the five studies using the chi-square test were quantitative (Azadi & 
Didly 2008; Pinto et al., 2010; Schempf & Strobino, 2009; Vucinovic et al., 2008) and 
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one study was qualitative (Walkup et al., 2009). Of these studies, the p value benchmark 
for establishing statistical significant was <0.05. The Mann-Whitney rank sum was also 
used for normally distributed and skewed data in the Azadi and Dildy (2008) and Pinto et 
al. (2010) studies, and for statistical data analysis of quantitative data in the Vucinovic et 
al., (2008) study.  The Smith et al. (2009) study used multivariate analysis to categorize 
variables between pregnant and post-partum women.  
Findings 
Three of the qualitative studies focused on negative pregnancy outcomes related 
to substance abuse. The three studies by Azadi and Dildy (2008), Pino et al. (2010), and 
Vicinovic et al., (2008) resulted in similar findings, and noted there were a significant 
number of births affected by substance abuse. Pino et al. (2010) stated that (19)% of 
pregnant women screened positive for drugs.  According to Pinto and colleagues (2010) 
adverse fetal outcomes were most likely to occur when illicit substances were used 
during pregnancy and manifested most commonly as low birth weight, and placental 
abruption.  
Five of the studies focused on treatment and screening. Three of the studies were 
quantitative (Pinto et al., 2010; Schempf & Strobino, 2009; Smith et al., 2009) and two 
were qualitative (Neushotz & Fitzpatrick, 2008; Walkup et al., 2009). The results of three 
studies were similar (Neushotz & Fitzpatrick,2008;, Schempf & Stobine,2009;Smith et 
al.2009); all found there to be limited screening, as well as, limited prenatal care for 
substance abusing mothers. Of those mothers who were screened and tested positive for 
drug use, there were neither interventions nor treatment programs available to pregnant or 
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postpartum women. Walkup et al. (2009) found evidence to support an in-home 
intervention for pregnant, American Indian women. This study followed the success rates 
of an in home perinatal support group that provided evidence of decrease in the number 
of positive perinatal drug screens in mothers that completed the program. 
Two literature reviews were also used for the purpose of strengthening an 
understanding of the available data. Greenfield et al. (2006) examined the literature 
containing characteristics associated with treatment outcomes in women with substance 
use disorders and found that women with substance use disorders are less likely over their 
lifetime to enter treatment compared to their male counterparts. Howell et al. (1998) 
conducted a literature review to determine the information on perinatal drug abuse 
available in 1998.  Howell also wanted to gain insight to the level of progress made in 
combating the social injustice called perinatal substance abuse. 
 In 1998, Howell et al. reported:  
The prevalence of perinatal illicit drug use is known to be about 5% of all 
pregnant women nationwide, with higher rates for selected subgroups. Local 
studies have shown much higher rates. Substance abuse is associated with 
poverty, with the substance abuse of significant others, and with family violence. 
Perinatal substance abusers experience poorer birth outcomes (p.196).  
Reports of both literature reviews agreed with the data found in the research 
studies. There were a significant number of perinatal substance abusers and perinatal 
substance abuse had a negative impact on the health of the mother, as well as, the child.  
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The greatest weakness found in all studies is unavoidable. It is not ethical to 
knowingly study women who are actively taking illicit drugs while pregnant. Therefore, 
all of the studies required collection of retrospective data. The studies also relied heavily 
on self-reported data. Many of the authors recognized this as an inherent weakness of the 
data.  Neushotz and Fitzpatrick (2008) did not clearly list a sample size. They reported 
the total patient population and the numbers of patients that each primary care provider 
treated annually. The authors also listed the numbers of those patients who were male and 
female, as well as, the numbers of females who had used illicit drugs. The reader 
assumed this was the control group, but it was not listed as such. There were potential 
biases in both of the studies (Pinto et al., 2010; Vucinovic et al., 2008) that focused on 
the effects of substance abuse on pregnancy. Those biases included body mass index not 
recorded in either study, which could affect birth weight and hypertensive disorders. Data 
on HIV and Hepatitis was not collected in the Pinto et al. (2010) study, but was in the 
Vucinovic et al. (2008) study. This is an important omission since HIV and Hepatitis can 
both affect birth outcomes also.  
Results 
Results of six studies reported the incidence of perinatal substance abuse, effects 
on pregnancy and neonatal outcomes,  as well as, the success of screening and treatment 
(Azadi & Dildy, 2008; Neushotz & Fitzpatrick, 2008; Pinto et al., 2010;  Schempf and 
Strobino, 2009; Smith et al., 2009; Vucinovic et al., 2008). Unanimously, they reported 
that perinatal substance abuse resulted in negative pregnancy outcomes such as preterm 
delivery, low birth weight, placental abruption, neonatal hemorrhagic stroke, and an 
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increased incidence of infection in the neonate. Walkup et al. (2009) found fewer reports 
of perceived stress or substance abuse in the mothers who received early pregnancy 
perinatal drug abuse 
      Characteristics of individual studies included in this paper are presented in 
Table A-1 Summary of Study Characteristics (See Appendix B). 
National Guidelines 
American College of Obstetricians and Gynecologists (2014) states “screening for 
substance abuse is a part of complete obstetric care and should be done in partnership 
with the pregnant woman. They also state “all women should be routinely asked about 
their use of alcohol and drugs, including prescription opioids and other medications used 
for nonmedical reasons” (p.2). The American Academy of Pediatrics (2013) states “the 
primary care pediatrician’s role in addressing prenatal substance use should include 
prevention, identification of exposure, recognition of medical issues for the exposed 
newborn infant, and regular follow-up to monitor any long-term effects” (p.a1009).The 
American Nurses Association (ANA), (2011) states “registered nurses working in the 
perinatal field to seek out appropriate rehabilitation and therapy treatment for women 
abusing substances (illicit or prescribed drugs, and/or alcohol) and to identify and offer 
appropriate therapy to infants exposed to these substances” (p.1). National certifying 
bodies, and national guidelines suggest that screening and intervention is necessary in 




The states of Minnesota has specific statues that pertain to perinatal drug testing. 
Statue 626.556, Reporting of maltreatment of minors reads:  
626.5561 REPORTING OF PRENATAL EXPOSURE TO CONTROLLED 
SUBSTANCES.§ Subdivision 1.Reports required. 
(a) Except as provided in paragraph (b), a person mandated to report under 
section 626.556, subdivision 3, shall immediately report to the local welfare 
agency if the person knows or has reason to believe that a woman is pregnant and 
has used a controlled substance for a nonmedical purpose during the pregnancy, 
including, but not limited to, tetrahydrocannabinol, or has consumed alcoholic 
beverages during the pregnancy in any way that is habitual or excessive. 
(b) A health care professional or a social service professional who is mandated to 
report under section 626.556, subdivision 3, is exempt from reporting under 
paragraph (a) a woman's use or consumption of tetrahydrocannabinol or alcoholic 
beverages during pregnancy if the professional is providing the woman with 




As the literature suggests, perinatal substance abuse can be seen in many settings 
in health-care. The policy designed from this DNP project will be universal to any health 
care provider, and will be able to be used in both the emergency department, and the 
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hospital at the project facility. The clinicians guided by this policy will need be educated 
in their specific settings. The project leader has used Laves Theory of Situational 
Learning in previous projects where collaboration and interaction were key components 
to learning. This project will require information presented to be specific to the project 
setting and will be best presented in the environment of the project site.  
Lave’s Theory of Situational Learning 
Lave’s Situational Learning Theory will be used as the theoretical framework to 
guide this project including the development of a perinatal drug abuse policy for the 
project site. Lave’s Theory of Situational Learning states that learning is situated, that is, 
as it normally occurs. Learning is embedded within our culture and activity and it is 
usually unintentional rather than deliberate (Knowledgebase, 2011). Situational Learning 
Theory is a practice theory that requires that learning take place in settings or situations 
that are normal to that environment. Practice theories are used in the actual delivery of 
patient care to clients. They are also used to carry out nursing interventions, as well as 
educating patients and staff, and communicating with patients and staff.  Social 
interaction and collaboration between all parties are essential components of Lave’s 
theory.  Situated learning requires that knowledge be presented in its authentic context, or 




Evidence Based Practice Model: The Sanford Way 
Conceptual Model 
The Sanford Way is a work improvement model that allows users to see 
improvement in a different way. This model focuses on initiating change by identifying 
opportunities for improvement, including the subjects of the change in planning the 
interventions, and substantiating change by monitoring and evaluating outcomes (Rodak, 
2012). Sanford Way Model of Change has three key components including people, 
process, and performance.  
Each component of the model has identified principles. The people component 
incorporates building people and their capacity for work, learn through relentless 
reflection and continuous improvement, make technology fit people, and support people 
by creating efficient and reliable processes. The process component includes eliminating 
waste, error-proofing systems, designing work where the safest process is the easiest, 
liberating human creativity by establishing standard work, and creating connected 
process flows to improve performance. The performance component aligns with Sanford 
Rational Standards, sustains change for reliable outcomes, and utilizes evidence-based 
practice (Rodak, 2012). This model will be used to develop a perinatal drug abuse policy 
















Figure 1. The Sanford Way model of quality improvement is an improvement 
methodology that allows us to identify improvement options that support the needs of all 
involved (Rodak, 2012). 
Summary 
Perinatal drug abuse directly causes poor, often devastating, birth outcomes 
(ASTHO, 2014). All health care providers will need the best tools possible to combat this 
critical health problem. There is a need at the project facility for a policy that guides 
providers to non-biased, screening, assessment, recognition, and intervention of perinatal 
drug abuse. The project site does not currently have a policy in place for perinatal drug 
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screening or intervention. Leadership organizations in the field of perinatal care suggest 
facilities adopt a policy when managing perinatal drug abuse, use, or suspected use. The 
development of a policy will support health care providers in using non-biased care to 
address this profound issue while promoting nursing theory guided practice, as well as 




Section 3: Approach 
Introduction 
The purpose of this project was to develop a policy for the project site that will 
enable providers (Nurse Practitioners and Physicians) to objectively screen child-bearing 
aged women for drug abuse, by providing hospital and emergency department caregivers 
the policy support needed to test for, and intervene with, positive drug screens  
This policy is needed to guide providers at the project to approach and intervene 
with this problem in a non-biased manor. This section will outline the process for 
curriculum development, implementation and evaluation of this quality improvement 
project. The following outlined the steps were taken to develop this project.  
1. Identify key stakeholders 
2. Assemble the team 
3. Identify barriers and limitations to the development of this policy 
4. Set Goals, objectives for perinatal drug abuse policy formation and guide the 
team to assess relevant evidence.  
5. Seek Institutional Review Board approval at study site and Walden.  
6. Develop the project site’s perinatal drug policy based on the Sanford Way 
model, national standards and recommendations, and special interest 
recommendations.  
7. Develop a plan for implementation of policy.  




Team members were chosen based on their knowledge, and by their investment in 
the project site, as well as their interest in quality improvement within the system. 
According to Kelly (2013), it is critical to identify and understand the systems structure 
and the structures influence on behavior. To have success in implementing lasting change 
efforts, it is important to press oneself to “go below the waterline”, meaning that if we 
target interventions to change what we do, rather than what causes the system to work the 
way it does, change will be temporary and we will not have “gone below the waterline” 
(Kelly, 2013, p. 36-38). The goal of this project will be to go below the waterline, thus 
implementing long standing change in the management of perinatal substance abuse. 
Team members for this quality improvement project will include: 
1. Team leader: The DNP student author of this project who will function as 
facilitator.  
a. Team leader will specifically develop policies and procedures and 
accompanying documents for perinatal drug abuse intervention. The 
team leader will develop the policy and procedure based on State and 
National guidelines as well as recommendation of local special interest 
groups.  
 
2. Administration representative/ CEO of Project Site  
a. Evaluation and implementation will be monitored/managed by the 
CEO or administrative representatives such as the CNO or QI officers.  
3. Chief Nursing Operator (CNO) at Project Site 
a. Evaluation and implementation will be monitored/managed by CNO or 
representative, administrative representatives, and the QI officer.  
 
4. Provider representative.  
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a. Implementation and continued participation will be the responsibility 
of participating providers.  
 
5. Quality Improvement (QI) Officer of Nursing.  
a. Evaluation and implementation will be monitored/managed by QI 
officer, the CNO representative, and the CEO Representative.  
 
Development of the project site’s Perinatal Drug Policy 
Ethical Considerations 
The researcher submitted all paperwork required to obtain approval from Walden 
Universities Internal Review Board (IRB), as well as the project site facilities 
management officers. Special consideration will be made to avoid any race-specific 
interventions in this policy.  
Developing the Policy 
Evidence leads to the recognition that there must be a policy in place for health 
care providers to address perinatal drug abuse. The lack of such a policy leaves providers 
vulnerable to the assumption of provider bias when perinatal drug abuse is recognized 
and interventions are ordered or implemented. Development of this policy was specific to 
the project site, and the needs of the community they serve. The policy is based on 
National and State guidelines, recommendations from both the American Academy of 
Pediatrics and American Academy of Obstetrics, American Nurses Association,  as well 
as local special interest groups. Stakeholders and team members were interviewed for 
input and opinion during the development phase of the policy. The policy will be 
reviewed for content and validity by the CEO as well as the medical committee. The 
policy will go through an approval process as all policies do at the project facility.  
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Planning Implementation of the Policy 
Project site stakeholders and leadership personnel were included in planning the 
implementation of the policy. Evidence for the need of a policy for perinatal drug abuse 
was presented to stakeholders and leadership. The policy was developed by the project 
leader and is specific to the project site. The project leader used current state and local 
laws, as well as evidenced based on guidelines set forth by ACOG, the American 
Academy of Pediatrics, and the ASTHO. Using the Sanford Way model for 
implementation, the project leader identified opportunities for improvement, included the 
subjects of the change in planning the interventions, and plans to sustain change by 
monitoring and evaluating outcomes (Rodak, 2012). 
Develop Evaluation Plan 
Evaluation of this perinatal drug abuse policy began in the planning phase of this 
project. This evaluation plan was discussed with the stakeholders in the early 
development stages.  Following are the suggested steps to be taken during this evaluation, 
the steps are varying and may be conducted simultaneously or cyclic (Hodges, 2011. p. 
210-211).  
1. Engage stakeholders 
2. Describe the program.  
3. Conceptualize the evaluation. 
4. Design the evaluation 
5.  Chose and test the instruments and procedures.  
6. Collect evaluation data.  
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7. Analyze and report data.  
8. Make changes to the program based on the data.  
9. Evaluate again.  
Evaluation will focus on the number of child-bearing aged women that are 
screened for pregnancy and perinatal drug abuse beginning at least six months prior to 
implementation of the policy, as well as six months after the implementation of the 
policy.   
Evaluation of the program is vital when planning and processing any project. 
Evaluation must help show program success, improvement, and whether the program is 
meeting its goals and objectives (Hodges, 2011). Evaluation of this policy will take place 
at a later time, and will not be part of this project.  
Summary 
Perinatal drug abuse is a profound problem faced in healthcare today. Providers at 
the project site do not have a policy in place to guide assessment, diagnosis and 
intervention of perinatal drug abuse. With the lack of policy, providers are vulnerable to 
the assumption of provider bias when intervening with perinatal drug abuse. Through 
nursing leadership, collaboration, and nursing policy development providers will be given 
the tools needed to assess, diagnose and intervene with perinatal drug abuse.
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Section 4: Findings, Discussions and Implications 
 
To recap, the was to develop a policy for the project site that will enable providers 
(Nurse Practitioners and Physicians) to objectively screen child-bearing aged women for 
drug abuse, by providing hospital and emergency department caregivers the policy 
support needed to test for, and intervene with, positive drug screens  
This project is relevant to nursing practice by alleviating the assumption of health 
care provider bias, as well as placing nurse leaders into position of policy development 
through promotion of nursing leadership. Development of system policy, by nurses, will 
positively impact the future of nursing mentorship within the nursing profession.  
The goal of this project was to impact social change by identifying and 
intervening with perinatal substance abuse, in system supported manor. This intervention 
will lead to better total wellbeing of communities, families and individuals suffering from 
perinatal drug abuse.  
The objectives of this project were to develop a policy for a critical access 
hospital, in a high risk area, who is currently operating without a policy, and who is 
currently leaving perinatal drug abuse intervention to individual decision, thus implying 
bias. This section will discuss the project and its implications, strengths and limitations, 
and the analysis of the DNP students self.  
 
Discussion of Project Product 
This facility policy was developed to intervene with perinatal drug abuse in a non-
biased manor, thus having a positive impact on perinatal drug abuse and improving 
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outcomes for communities, providers, and patients. The policy was developed taking 
recommendations from national guidelines set forth by accredited bodies as well as from 
stakeholders at the facility, and special interest stakeholders from the community.  
Discussion of Findings 
Program Development 
After receiving IRB approval from Walden University, the project leader in 
motion a series of meetings with project site stakeholders. Meetings included face-to-face 
visits, telephone conference, emails conversations, and group meetings. Meetings were 
attended by DNP student (project leader) and site stakeholders (including the CEO, CNO, 
QI Nurse, and special interest representatives from the community). During these 
meetings, a perinatal drug abuse policy was discussed; input from these stakeholders, 
available literature and national guidelines, guided the development of this policy.  
The policy was written in the format used by this facility for policy development. 
National guidelines recommend that every health care facility have a policy that protects 
providers from the assumption of bias when screening for perinatal drug abuse. The data 
collected suggested there are specific adverse outcomes that can be seen with perinatal 
drug abuse such as vascular accidents, placental abruption, preterm labor, perinatal infant 
mortality, and hypertension in pregnancy to name a few. These specific adverse outcomes 
were included in the policy. There is significant evidence that child-bearing aged women 
are at risk for perinatal drug abuse. Kuczkowski (2007) reported ‘in the United States 
nearly 90% of drug-abusing women are of reproductive age. Polysubstance abuse is very 
common” (p. 578).  
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The community in which this project site lies is affected by perinatal drug abuse 
at a higher rate than state average, it is estimated that this community has a 60% greater 
chance of perinatal drug abuse than other Minnesota communities (Enger, 2014). This 
project site is the only hospital or emergency department located for more than 60 miles 
of this service community. This facility does not perform prenatal care or labor and 
delivery care; they transfer patients to regional delivering centers. In 2010, nearly 3 
percent of mothers delivering at the two closest regional delivering facilities tested 
positive for drugs the day of their child's birth. In 2013, that number more than doubled 
to more than 6.5 percent (Enger, 2014). This community was recognized to have greater 
than average need for perinatal drug abuse intervention and a grant was given to one of 
the regional delivery centers for a 1.6 million dollar perinatal drug intervention program 
(Enger, 2014). Stakeholders in this community have recognized the need for immediate 
intervention in perinatal drug abuse at the project site as well. 
Currently, providers at the project site are left to determine the need to screen for 
pregnancy or perinatal drug abuse at their own personal discretion. There is no policy in 
place to guide that determination. This leaves providers vulnerable to the assumption of 
bias when determining the need for pregnancy or drug screens. The development of this 
policy will alleviate the assumption of bias and provide the community with appropriate, 




The developed policy will require that any  female of child bearing age (14-55), 
presenting to the ED for; (a) drug overdose (intentional or un-intentional), (b) those 
needing treatment with a schedule I-IV medication have a pregnancy screen. Perinatal 
patients that presents to the ED with the following conditions must have a drug screen 
(which could include a quantitative screen if the provider feels this is appropriate): (a) 
those in labor or have delivered prior to admittance, (b) placental abruption, (c) evidence 
of unexplained or poor weight gain in pregnancy, (d) MI or CVA in a child bearing aged 
woman, or HTN in pregnancy, (e) admitting to, or evidence of, poor or no prenatal care, 
(f) admitting to illicit drug abuse, (g) fetal demise, (h) at the request of county or tribal 
social services,  (i) if health care provider exam, or history intake dictates. 
Implementation Plan 
The policy was developed specifically for the project site. The project team 
recognized the need for a policy and accepted the presentation of the project and agrees 
with the need for a policy. Senior leadership at the project site identified the need for a 
policy as a priority, and agreed that the groundwork has been laid for policy 
implementation. 
Although the developed policy was submitted to the project site, senior leadership 
has voiced their understanding that project evaluation is needed and they will decide 
when or if the project site will ultimately implement the policy. An evidence based 
evaluation plan was proposed to the team of stakeholders, along with the project. The 
evaluation plan reflects that which was laid out in the project proposal. During project 
planning meetings, it was often voiced that there is much work to do in the future of 
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perinatal drug abuse at the project site. Access to follow up, post hospital care, and 
treatment were recognized as the greatest future concerns for the project site. The policy 
can be referenced in Appendix A. 
Evaluation Plan 
Evaluation of the project was also presented to the project team. Planning for 
evaluation began at the onset of the project. The evaluation plan presented suggests that 
drug screens, as well as pregnancy screens, are tracked for six months prior to and after 
implementation of the policy. If at any time during the evaluation leadership identifies 
concerns for the policy, changes could be made to the policy that will promote perinatal 
drug use interventions. It is suggested that tracking of drug and pregnancy screens be 
completed by nursing staff via the electronic medical record.   
Specifically, it is suggested that for a period of 6 months before and after 
implementation of the project, a log of every female of child bearing age, that presents to 
the ED for (a) drug overdose (intentional or un-intentional), (b) those needing treatment 
with a schedule I-IV medications and have a pregnancy screen. It is also suggested that 
the log record all perinatal patients that present to the ED with the following conditions 
which require a drug screen (a) those in labor or have delivered prior to admittance, (b) 
placental abruption, (c) evidence of unexplained or poor weight gain in pregnancy, (d) 
MI or CVA in a child bearing aged woman, or HTN in pregnancy, (e) admit to or 
evidence of poor or no prenatal care, (f) admitting to illicit drug abuse, or (g) at the 
request of county or tribal social services.  
35 
 
It is suggested this log be kept for six months prior and six months after 
implementation of the policy. 
Implications 
Practice 
This DNP project has used evidence to identify the need for policy development. 
This project allowed this student to lead a team of stakeholders and to develop a policy 
that will lead to practice change at the project facility.  Policy development by DNP 
prepared nurses is needed to elevate the professional status of nursing. Bartels (2005) 
stated “the AACN has adopted a new position that recognizes the DNP degree as the 
highest level of preparation for clinical practice” (p 233). DNP nurse leaders are 
encouraged to become active in leadership, and policy development. As a DNP student, 
and through the DNP curriculum, this student learned to recognize practice problems, and 
can utilize the skills needed to translate evidence into practice problem solutions.  
This project allowed the student to develop a policy that will positively impact the 
current perinatal drug abuse problem facing practitioners at the project site; it will also 
eliminate the suspect of provider bias. This is a health problem that the student feels 
passionate about intervening with. As this student has lived and worked in this 
community her entire life, she has personally seen the devastating effects of perinatal 
drug abuse. The student has also experienced the unfortunate consequences of drug 
screening without a policy, and being accused of biased behavior when doing so.  
Screening and testing for perinatal drug abuse can be difficult. Prasad (2014) 
stated, “Despite the adverse outcomes associated with exposure to tobacco, alcohol, and 
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illicit drugs, only approximately 20% of ob/gyns effectively screen patients for illicit 
drug use” (n.p.). Prasad (2014) identified provider embarrassment, fear of upsetting 
patients, and uncertainty of where to turn with positive results as barriers to screening.  
Policy Development 
Creating a perinatal drug screening policy is supported by the literature as 
evidenced by recommendations from professional organizations that lead health care 
policy. After a thorough review of the evidence, and referring to national guidelines, as 
well as meeting with both project site and community stakeholders, a policy for perinatal 
drug abuse screening was developed for the project site. This project will positively 
impact provider practice by intervening with the escalating health problem of perinatal 
drug abuse while eliminating provider bias. 
Future Research  
Research supports a policy for perinatal drug screening. Future research 
anticipated to stem from this project will include perinatal drug abuse treatment, and long 
term substance abuse care. Project site stakeholders have identified the need for future 
research into long term intervention, and management of perinatal drug abuse, as a 
priority problem for this project site.  
Social Change 
The nursing profession claims is founded on evidence-based practice. From the 
times of Florence Nightingale nurses have used evidence-based practice to guide clinical 
decision making (White, 2012). The rural health setting is a perfect setting for nurses 
(who are not known to be policy makers), to use evidence-based practice and take a 
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leadership role in policy development. Rural health nurse practitioners are required to 
practice at the top of their scope using autonomous, evidence-based practice. It is 
important for rural health NPs to use their experience and knowledge to guide policy 
development, and change the culture of policy making to be nursing driven. This 
evidence based practice policy allows nursing to take a leadership role in policy 
development.  
Strengths and Limitations 
There are many strengths to this DNP practice project. An evidenced based 
practice policy will allow providers to screen for, and intervene with, perinatal drug 
abuse in a non-biased manor. It will give providers comfort knowing they are intervening 
with this significant, complex health care problem, but also are protected from the 
pressures of bias. Currently, providers at the project site have no policy in place and are 
simply intervening based on their own personal knowledge and preference. This project 
is strengthened yet by the fact that it was developed based on up-to-date research, 
national and special interest recommendations, and state law.  
Limitations of the project include that is developed for a particular site, and is less 
generalizable for other rural health facilities. The project will delivered to site leadership 
and will be implemented at their discretion, if at all.  
Analysis of Self 
In pursuit of my doctoral degree, I have felt significant personal and professional 
growth. I have worked as a rural health NP for the past five years. I have worked without 
a policy for perinatal drug abuse that entire time. Unfortunately, I have been involved in 
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situations where I myself have been accused of personal bias when intervening with 
perinatal drug abuse without a policy. This DNP project has given me the opportunity to 
impact this truly devastating community health problem, while pushing myself into a 
nurse leadership role. I recognize that nurses are not predominantly policy makers. I felt a 
personal need to focus my project on policy development, and was very happy that my 
project can impact perinatal drug abuse, and support nurses and physicians alike by 
eliminating the suspicions of bias. 
Summary 
Perinatal drug abuse is rapidly becoming one of the most profound issues facing 
the health and wellbeing of neonates. Provider recognition of, and intervention for, 
perinatal drug abuse is often left to provider discretion and bias. Without a policy in place 
to guide health care providers, the assumption of bias can be detrimental to intervention. 
This policy project will support health care providers at the project site, and encourage 
them to intervene with perinatal drug abuse and every possible encounter.  










Section 5:  
Project Summary 
Introduction  
Perinatal drug abuse is rapidly becoming one of the most profound issues facing 
the health and wellbeing of neonates. Provider recognition of, and intervention for, 
perinatal drug abuse is often left to provider discretion and bias. Policy to recognize, 
assess, and intervene in perinatal drug abuse is necessary for all providers, and will 
alleviate any potential provider bias, as well as provide guidance and direction for 
intervention. 
Project Goal 
The primary project goal is to develop a policy for the project site that will enable 
providers (Nurse Practitioners and Physicians) to objectively screen child bearing aged 
women for drug abuse, by providing hospital and emergency department caregivers the 
policy support needed to test for, and intervene with, positive drug screens. Specific 
objectives for this project will be to develop a perinatal drug abuse policy based on 
National Guidelines established by the American Academy of Pediatrics, American 
Academy of Obstetrics, RNAO, evidence (Cochrane reviews), state law, and local tribal 
government recommendations.  
Approach  
This quality improvement project engaged a team of stakeholders which included 
both facility and community representatives, using evidence based practice, developed a 




An evidence based practice policy was developed that will support providers 
screening, testing, and intervening with perinatal drug abuse, protecting provider from 
assumption of bias.  
Implication for practice 
Nurses are not typically strong in policy development and are historically known 
to “shy away from leadership opportunities” (Mason, 2013, p. xxvii). Doctorate-prepared 
nurses are called upon to lead their field in policy development and social change. 
Development of system policy, by nurses, will positively impact the future of nursing 
mentorship within the nursing profession. Nursing is working diligently to develop a 
culture of nursing mentorship within this profession that goes above and beyond the 
individual and organizational level (Montavlo, 2015).  
Background, Purpose and Nature of the Project 
Background 
Perinatal drug abuse is a growing problem for all communities in the United 
States. The project facility is a critical access emergency department, hospital and rural 
health clinic located in northern Minnesota. The county in which the facility lies is within 
the borders of an Indian Reservation, The project facility does not currently have a policy 
on perinatal drug testing or perinatal drug use intervention. The current status quo is to 
leave all perinatal drug screening to the determination of the provider, leaving the 




According to Association of State and Territorial Health Officials (ASTHO) 
(2014), “taking a public health approach to routine screening for unhealthy substance use 
in women at every healthcare visit can help increase the opportunities for primary 
prevention” (p. 2). The purpose of this project was to develop a policy for the project site 
that will enable providers (Nurse Practitioners and Physicians) to objectively screen 
child-bearing aged women for drug abuse, by providing hospital and emergency 
department caregivers the policy support needed to test for, and intervene with, positive 
drug screens.   
Nature of the Project 
Evidence leads to the recognition that there must be a policy in place for health 
care providers to address perinatal drug abuse. The lack of such a policy leaves providers 
vulnerable to the assumption of provider bias when perinatal drug abuse is recognized 
and interventions are ordered or implemented. Development of this policy was specific to 
the project site, and the needs of the community they serve. The policy is based on 
National and State guidelines, recommendations from both the American Academy of 
Pediatrics and American Academy of Obstetrics, American Nurses Association,  as well 
as local special interest groups, and state and local law. Stakeholders and team members 
were interviewed for input and opinion during the development phase of the policy. 
Project Design and Setting 
This DNP Project was designed to be implemented by providers at the project 
site. The project began by meeting with project site management and determining the 
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greater need at the project. Perinatal drug abuse intervention was identified as a great 
need at the project site. Extensive review of the evidence revealed that intervention must 
be supported by policy to prevent suspicion of provider bias. After receiving approval by 
the project site and Walden University’s Institutional Review board, a team of project site 
leadership, community stakeholders and the project leader were called upon for advice 
throughout policy development. 
Interpretation of Results 
A policy for perinatal drug abuse screening and intervention is imperative to 
protect providers from assumption of bias. Lindsay (2013) recommended “parturients 
identified as drug users” receive a comprehensive management approach involving both 
“high risk obstetrics, and comprehensive counseling” (p. 140). Recognition of this 
profound social problem has healthcare leaders pushing for universal screening of all 
child bearing aged women, and certainly for all pregnant women. ASTHO (2014) stated:  
States can support the American Congress of Obstetricians and Gynecologists’ 
(ACOG) recommendation for universal substance use screening in early 
pregnancy in a variety of ways. State agencies, quality improvement efforts, and 
perinatal collaborative can advance prenatal screenings as the expected standard 
of care for obstetric providers. State health agencies can ensure that Medicaid 
reimburses for substance abuse screening, support provider education and 
training, and streamline entry points for substance abuse treatment (p.6).  
The literature regarding perinatal substance abuse has proved consistent results. 
There is a national, as well as, global need for interventions surrounding perinatal 
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substance abuse. In addition, there is a need for further screening and policies for drug 
screening and testing, which are specific to women, and pregnant women. 
American College of Obstetricians and Gynecologists (2014) states “screening for 
substance abuse is a part of complete obstetric care and should be done in partnership 
with the pregnant woman. They also state “all women should be routinely asked about 
their use of alcohol and drugs, including prescription opioids and other medications used 
for nonmedical reasons” (p. 2). The American Academy of Pediatrics (2013) stated “the 
primary care pediatrician’s role in addressing prenatal substance use should include 
prevention, identification of exposure, recognition of medical issues for the exposed 
newborn infant, and regular follow-up to monitor any long-term effects” (p.a1009).The 
American Nurses Association (ANA), (2011) stated “registered nurses working in the 
perinatal field to seek out appropriate rehabilitation and therapy treatment for women 
abusing substances (illicit or prescribed drugs, and/or alcohol) and to identify and offer 
appropriate therapy to infants exposed to these substances” (p. 1). National certifying 
bodies, and national guidelines suggest that screening and intervention is necessary in 
appropriate treatment of perinatal drug abuse.  
Implication for Practice 
This DNP project has used evidence to identify the need for policy development. 
This project allowed me to lead a team of stakeholders, and to develop a policy that will 
lead to practice change at the project facility.  Policy development by DNP prepared 
nurses is needed to elevate the professional status of nursing. Bartels (2005) stated “the 
AACN has adopted a new position that recognizes the DNP degree as the highest level of 
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preparation for clinical practice” (p. 233). DNP nurse leaders are encouraged to become 
active in leadership, and policy development. As a DNP student, and through the DNP 
curriculum, I have learned to recognize practice problems, and can utilize the skills 
needed to translate evidence into practice problem solutions.  
Conclusion 
This DNP project resulted in the development of an evidence based practice 
policy that will support providers at the project site, minimizing assumption of bias and 
will meet the needs of the community by positively intervening with perinatal drug abuse.  
Perinatal drug abuse is a significant community health problem that will require 
intervention at every opportunity. Without this evidence based project, the facility and its 
surrounding communities are at risk of missing the opportunity to intervene with 
perinatal drug abuse, and providers are at risk for the assumption of bias. Upon final 
approval, and meeting all requirements of this DNP degree, the policy will be submitted 
to the facility site (along with a 12 month evaluation plan) with the hopes that the project 
site will follow the evidence, support their providers and community, and implement this 
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Title: Perinatal Drug Abuse Intervention: Policy for Drug Screening 
Created: 10/2015 
PURPOSE: To provide policy and procedure for perinatal drug abuse screening.  
Definitions:  
Childbearing aged women: for this policy that will include women ages 14-55.  
Poor or no prenatal care: defined as less than two prenatal visit in their first trimester, less 
than one per month in their second trimester, and less than two visits per month in their 
third trimester.  
Policy:  
Urine drug screen will be ordered by the facility provider based on criteria stated in this 
policy, as well if the medical or psychosocial assessment made by the provider indicates 
the necessity. 
 If substance abuse is discovered, proper medical, social and mental health support will 
be provided, and reporting will comply with Minnesota State Statues 626.556 and 
626.5561, “Reporting of Maltreatment of Minors” and “Reporting of Perinatal Exposure 
to Controlled Substances”.  
Procedure:  
1) Admitting nurse, and provider will screen any childbearing aged women for 
perinatal drug abuse.  
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2) On the occasion that any of the following factors are identified, a urine pregnancy 
test, as well as urine toxicology screen, will be collected. 
Drug overdose (intentional or un-intentional), (b) those needing 
treatment with a schedule I-IV medication, (c) any identified, or 
clinical suspicion of, illicit drug use in a child bearing aged woman. 
3) Perinatal (or known pregnant) patients that presents to the ED with the following 
condition(s) must have a drug screen (which could include a quantitative screen if 
provider feel this is appropriate).  
(a) Those in labor or have delivered prior to admittance, (b) placental 
abruption, (c) evidence of unexplained or poor weight gain in 
pregnancy, (d) MI, CVA or unexplained tachycardia in a child bearing 
aged woman, or HTN in known pregnancy, (e) admittance to, or 
evidence of, poor or no prenatal care, (f) admitting to illicit drug 
abuse, or (g) fetal demise, or (h) at the request of county or tribal 
social services. 
4) Although informing the patient is preferred, the drug screen does not require 
patient or parent permission.  
5) The facility social worker will be notified of confirmed perinatal drug abuse, and 
will notify the appropriate Human Services, Child Protection, or Indian Child 
Welfare office. This report will be submitted, in writing, within 72 hours of the 
visit.  
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OBJECTIVE: Provided as an attachment to Capstone Project intended to meet the 
requirements of graduation from Walden University, DNP Program.  
QUALIFICATIONS: I am a certified Family Nurse practitioner with Sanford 
Health Systems. I am a motivated, skilled, compassionate and determined. I have lived in 
this community my entire life, and am vested in the health and wellness of this 
community.   
EDUCATION 
 1999-2001 Diploma in Nursing, LPN, Itasca Community College 
 2001-2002 Associate Degree, RN, Northland Community and Technical  
  College 
 2006-2008 Bachelor of Science Degree, BSN, Bemidji State University 
 2008-2011 Master Degree, MSN, University of North Dakota   
 2013-Current Enrolled at Walden University, DNP program expected  






2001-2002 LPN, Clearwater County Memorial Hospital- Bagley Minnesota 
Clearwater County hospital is a rural county hospital that has approximately fifteen beds. 
As an LPN at Clearwater Hospital my responsibilities included assessments, med pass, 
ADLs, assisting in the Emergency Room, lab, and x-ray. Working in a rural hospital 
helped to build the foundation of my nursing experience in such a way as to promote 
critical thinking as the driving force of my care.  
2002-2011 RN, North Country Regional Hospital – Bemidji Minnesota.  I was 
employed in Outpatient Surgery and Recovery Room. Responsibilities included the 
assessments and admissions of surgical patients both inpatient and out. I work half of my 
hours in admissions and half in recovery. Our Recovery Room is a critical care area 
where as an RN I am responsible for the care of all surgical cases. Assessment and 
patient advocacy are my most utilized skill. 
I was employed on the Family Care Center at North Country. Family Care Center 
consists of three separate areas; 1-Med/Surg.  2. Pediatrics and 3. Labor and Delivery, 
Newborn Nursery and Post Partum.  On family care I spent the first year working as a 
staff RN on the Med-Surg. /Pediatrics floor. Following one year of experience I began 
working primarily in Labor and Delivery. During the last three years of my employment 
on Family Care worked as the fulltime Night Charge Nurse for the Family Care Center 
which consisted of being the charge nurse for all three areas of the department.  In 2007 I 
transferred departments and began working in the OPS/PACU department. PACU is a 
critical care department in which I served as a fulltime BSN.  
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In 2008 I served as adjunct faculty at Northland Community and Technical 
College. Summer session 2008 I taught Maternal Child Health and Adult Nursing II on 
the Mahnomen Minnesota Campus. Fall 2008 I served as a structured tutor to the 
Graduating RN students on the Thief River Falls Minnesota campus. 
In 2010 I served as a GTA (Graduate Teaching Assistant) at the University of 
North Dakota. I served as a Clinical Instructor for the Postpartum and Newborn     
clinical rotation. As well as lead discussion group twice weekly. I was also responsible 
for the correction and grading of the student care plans and portfolios.    
2011-2015 I worked as an FNP for Sanford Health Systems, at the project site. I 
am a skilled FNP working full time as family practice provider in the clinic and ED 
setting. The project site is the primary hospital and ED caring for the residents of a large 
Indian Reservation.  
In August 2014 I taught at Bemidji States University as faculty for advanced 
skills II and clinical II.  
9/2015- Present: I transferred within Sanford system to Thief River Falls clinic 
where I am working two days per week in Internal Medicine clinic and two days per 
week in Urgent Care. I also cover the Emergency Department one weekend per month.  
8/2015- Present I began teaching with Northland Community and Technical 
College in the Associate RN program. I am teaching Clinical I and Clinical II currently.  
OTHER QUALIFICATIONS 
I currently hold ACLS, PALS and CALS certifications. I am certified to implant 
Nexplanon and Merena birth control.   
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2013- present I have been working in collaborative effort with White Earth 
Chemical Dependency, White Earth Mental health, Mahnomen Social services, Indian 
Child Welfare and the Department of Health to create a community based, collaborate 
approach to substance abuse on the White Earth Reservation. This group has actively 
taken a role in the recent opening of Odapinaan Giwiidookage Onijinaan, a residential, all 
male, inpatient addiction/treatment facility among many other substance abuse programs 
and interventions within our community. The goal of this collaborative effort is to open a 
detox center, and inpatient female residential program as well.  
I served as the President of the Board of Directors for Bagley Youth Hockey 
association and have been on the board since 5/2004. In 2007 and 2008 I served as the 
student representative to Bemidji State University, Department of Nursing’s Advisory 
Board. I assisted Clearwater County Nursing Services in surveillance and implementation 
of their county health survey, fall 2007.   
 
